Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dasatinib and Peg-Interferon Alpha 2b in First Line CML
NCT01872442Phase 2Completed
- Sponsor
- CHU de Poitiers
- Start
- Oct 2013
- Primary completion
- Oct 2018
- Modality
- Fragment-Derived Small Molecules, Polymer-based Nanoparticles, Allosteric Modulators
01
Overview
Phase 2, open-label, single-arm trial of dasatinib and peginterferon alfa-2b in chronic myeloid leukemia (CML), sponsored by CHU de Poitiers. Primary endpoint: Cumulative rate of molecular response at 12 months. Started Oct 2013; status: completed.
02
Drugs
dasatinibpeginterferon alfa-2b
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT01872442.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01872442.